Ascendis Pharma A (ASND) Net Income (2014 - 2026)
Ascendis Pharma A (ASND) posted Net Income of -$849.6 million for Q1 2026, down 3577.3% sequentially from -$23.1 million in Q4 2025, and down 773.15% YoY from $126.2 million in Q1 2025.
Ascendis Pharma A (ASND) Net Income (2014 - 2026) Analysis & Trends
Ascendis Pharma A has reported Net Income for 13 years, with the latest figure at -$849.6 million in Q1 2026.
- Quarterly Net Income fell 773.15% year-over-year to -$849.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$970.8 million (down 169.6% YoY) and the FY2025 annual result came in at -$293.7 million, up 25.38% from the prior year.
- Net Income eased to -$849.6 million in Q1 2026 per ASND's latest filing, from -$23.1 million in the prior quarter.
- Over five years, Net Income peaked at -$23.1 million in Q4 2025 and troughed at -$849.6 million in Q1 2026.
- A 5-year average of -$151.4 million and a median of -$116.3 million in 2023 frame the typical range for Net Income.
- The sharpest annual moves came in 2025 and 2026: Net Income soared 69.93% in 2025, then tumbled 773.15% in 2026.
- Over 5 years, Net Income stood at -$200.7 million in 2022, then soared by 59.64% to -$81.0 million in 2023, then surged by 52.12% to -$38.8 million in 2024, then surged by 40.44% to -$23.1 million in 2025, then plunged by 3577.3% to -$849.6 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$849.6 million, -$23.1 million, and -$62.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | -849.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -849.60 Mn |
| Dec 31, 2025 | -23.10 Mn |
| Sep 30, 2025 | -62.84 Mn |
| Jun 30, 2025 | -35.27 Mn |
| Mar 31, 2025 | -97.30 Mn |
| Dec 31, 2024 | -38.79 Mn |
| Sep 30, 2024 | -106.70 Mn |
| Jun 30, 2024 | -117.30 Mn |
| Mar 31, 2024 | -136.90 Mn |
| Dec 31, 2023 | -81.01 Mn |
| Sep 30, 2023 | -175.19 Mn |
| Jun 30, 2023 | -133.17 Mn |
| Mar 31, 2023 | -116.26 Mn |
| Dec 31, 2022 | -200.71 Mn |
| Sep 30, 2022 | -172.75 Mn |
| Jun 30, 2022 | -86.87 Mn |
| Mar 31, 2022 | -140.85 Mn |
| Dec 31, 2021 | -121.33 Mn |
| Sep 30, 2021 | -94.75 Mn |
| Jun 30, 2021 | -161.82 Mn |